Due to the unexpected passing of actor Chadwick Boseman on August 28, there has been a renewed interest in young-onset colorectal cancer. Mr. Boseman, known for his roles in Black Panther, Marshall, and Get on Up, was only 43 when he died from colon cancer. This week, we'll go back in The ASCO Post Podcast archives and hear from Kimmie Ng, MD, MPH, who was first on the show about a year ago, offering her insights on the rising rates of colorectal cancer in young adults.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Due to the unexpected passing of actor Chadwick Boseman on August 28, there has been a renewed interest in young-onset colorectal cancer. Mr. Boseman, known for his roles in Black Panther, Marshall, and Get on Up, was only 43 when he died from colon cancer. This week, we'll go back in The ASCO Post Podcast archives and hear from Kimmie Ng, MD, MPH, who was first on the show about a year ago, offering her insights on the rising rates of colorectal cancer in young adults.

This week on The ASCO Post Podcast, we'll first hear about a study of the monoclonal antibody sintilimab in combination with pemetrexed and platinum to treat advanced nonsquamous non–small cell lung cancer. Then we'll review the results of the CheckMate 743 trial, which suggest a new standard of care in first-line treatment of unresectable malignant pleural mesothelioma.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week on The ASCO Post Podcast, we'll first hear about a study of the monoclonal antibody sintilimab in combination with pemetrexed and platinum to treat advanced nonsquamous non–small cell lung cancer. Then we'll review the results of the CheckMate 743 trial, which suggest a new standard of care in first-line treatment of unresectable malignant pleural mesothelioma.

We'll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we'll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.

Coverage of stories discussed this week on ascopost.com:

Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence

Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> We'll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we'll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.

We'll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we'll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.

Coverage of stories discussed this week on ascopost.com:

Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence

Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

We'll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we'll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.

Coverage of stories discussed this week on ascopost.com:

Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence

Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence

We'll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we'll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.

Coverage of stories discussed this week on ascopost.com:

Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence

Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma

This week, we'll start with a follow-up analysis of pathologic complete response in patients participating in the I-SPY2 trial. Then, we'll move on to a study that sought to answer whether a longer time from diagnosis to surgical treatment lowered overall survival in women with early-stage breast cancer. Last, we'll hear about how the COVID-19 pandemic is worsening disparities in cancer care among racial and ethnic minorities and the medically underserved.

Coverage of stories discussed this week on ascopost.com:

Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer

Increased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll start with a follow-up analysis of pathologic complete response in patients participating in the I-SPY2 trial. Then, we'll move on to a study that sought to answer whether a longer time from diagnosis to surgical treatment lowered overall survival in women with early-stage breast cancer. Last, we'll hear about how the COVID-19 pandemic is worsening disparities in cancer care among racial and ethnic minorities and the medically underserved.

This week, we'll start with a follow-up analysis of pathologic complete response in patients participating in the I-SPY2 trial. Then, we'll move on to a study that sought to answer whether a longer time from diagnosis to surgical treatment lowered overall survival in women with early-stage breast cancer. Last, we'll hear about how the COVID-19 pandemic is worsening disparities in cancer care among racial and ethnic minorities and the medically underserved.

Coverage of stories discussed this week on ascopost.com:

Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer

Increased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we'll start with a follow-up analysis of pathologic complete response in patients participating in the I-SPY2 trial. Then, we'll move on to a study that sought to answer whether a longer time from diagnosis to surgical treatment lowered overall survival in women with early-stage breast cancer. Last, we'll hear about how the COVID-19 pandemic is worsening disparities in cancer care among racial and ethnic minorities and the medically underserved.

Coverage of stories discussed this week on ascopost.com:

Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer

Increased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer

This week, we'll start with a follow-up analysis of pathologic complete response in patients participating in the I-SPY2 trial. Then, we'll move on to a study that sought to answer whether a longer time from diagnosis to surgical treatment lowered overall survival in women with early-stage breast cancer. Last, we'll hear about how the COVID-19 pandemic is worsening disparities in cancer care among racial and ethnic minorities and the medically underserved.

Coverage of stories discussed this week on ascopost.com:

Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer

Increased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Increased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease

This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

American Cancer Society Updates Guideline for Cervical Cancer Screening

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

American Cancer Society Updates Guideline for Cervical Cancer Screening

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

American Cancer Society Updates Guideline for Cervical Cancer Screening

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> American Cancer Society Updates Guideline for Cervical Cancer Screening

This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

American Cancer Society Updates Guideline for Cervical Cancer Screening

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced

This week, we'll review recommendations from a new guideline issued by the American Cancer Society on cervical cancer screening. Then, we'll discuss the FDA's approval of a triplet therapy for advanced melanoma. Lastly, we'll hear a summary of a panel discussion on telehealth for patients with cancer during the COVID-19 pandemic.

Coverage of stories discussed this week on ascopost.com:

American Cancer Society Updates Guideline for Cervical Cancer Screening

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> BRAF V600–Mutated Melanoma

This week, we'll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we'll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus. Last, we'll review the FDA's recent approval of a CAR T-cell immunotherapy for patients with relapsed or refractory mantle cell lymphoma.

Coverage of stories discussed this week on ascopost.com:

First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer

Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?

FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we'll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus. Last, we'll review the FDA's recent approval of a CAR T-cell immunotherapy for patients with relapsed or refractory mantle cell lymphoma.

This week, we'll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we'll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus. Last, we'll review the FDA's recent approval of a CAR T-cell immunotherapy for patients with relapsed or refractory mantle cell lymphoma.

Coverage of stories discussed this week on ascopost.com:

First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer

Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?

FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we'll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we'll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus. Last, we'll review the FDA's recent approval of a CAR T-cell immunotherapy for patients with relapsed or refractory mantle cell lymphoma.

Coverage of stories discussed this week on ascopost.com:

First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer

Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?

FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer

This week, we'll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we'll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus. Last, we'll review the FDA's recent approval of a CAR T-cell immunotherapy for patients with relapsed or refractory mantle cell lymphoma.

Coverage of stories discussed this week on ascopost.com:

First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer

Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?

FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?

This week, we'll discuss a study that compared two combination treatments for previously untreated patients with localized pancreatic cancer. Then, we'll explore whether a longer-established diagnosis of cancer is associated with higher risk of severe COVID-19 infection or death from the virus. Last, we'll review the FDA's recent approval of a CAR T-cell immunotherapy for patients with relapsed or refractory mantle cell lymphoma.

Coverage of stories discussed this week on ascopost.com:

First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer

Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?

FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma

This week, we'll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we'll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we'll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.

Coverage of stories discussed this week on ascopost.com:

Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma

Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we'll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we'll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.

This week, we'll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we'll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we'll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.

Coverage of stories discussed this week on ascopost.com:

Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma

Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we'll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we'll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we'll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.

Coverage of stories discussed this week on ascopost.com:

Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma

Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma

This week, we'll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we'll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we'll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.

Coverage of stories discussed this week on ascopost.com:

Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma

Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted

This week, we'll discuss the efficacy of the combination of lenvatinib and pembrolizumab for patients with advanced gastric cancer. We'll also highlight key points from the recent USPSTF draft recommendation on CT screening for lung cancer. Finally, we'll review a regulatory approval in metastatic bladder cancer and hear from the principal investigator of the confirmatory trial.

Coverage of stories discussed this week on ascopost.com:

Lenvatinib Plus Pembrolizumab for Advanced Gastric Cancer

USPSTF Issues Draft Recommendation Statement on Screening for Lung Cancer

FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll discuss the efficacy of the combination of lenvatinib and pembrolizumab for patients with advanced gastric cancer. We'll also highlight key points from the recent USPSTF draft recommendation on CT screening for lung cancer. Finally, we'll review a regulatory approval in metastatic bladder cancer and hear from the principal investigator of the confirmatory trial.

This week, we'll discuss the efficacy of the combination of lenvatinib and pembrolizumab for patients with advanced gastric cancer. We'll also highlight key points from the recent USPSTF draft recommendation on CT screening for lung cancer. Finally, we'll review a regulatory approval in metastatic bladder cancer and hear from the principal investigator of the confirmatory trial.

Coverage of stories discussed this week on ascopost.com:

Lenvatinib Plus Pembrolizumab for Advanced Gastric Cancer

USPSTF Issues Draft Recommendation Statement on Screening for Lung Cancer

FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we'll discuss the efficacy of the combination of lenvatinib and pembrolizumab for patients with advanced gastric cancer. We'll also highlight key points from the recent USPSTF draft recommendation on CT screening for lung cancer. Finally, we'll review a regulatory approval in metastatic bladder cancer and hear from the principal investigator of the confirmatory trial.

Coverage of stories discussed this week on ascopost.com:

Lenvatinib Plus Pembrolizumab for Advanced Gastric Cancer

USPSTF Issues Draft Recommendation Statement on Screening for Lung Cancer

FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> USPSTF Issues Draft Recommendation Statement on Screening for Lung Cancer

This week, we'll discuss the efficacy of the combination of lenvatinib and pembrolizumab for patients with advanced gastric cancer. We'll also highlight key points from the recent USPSTF draft recommendation on CT screening for lung cancer. Finally, we'll review a regulatory approval in metastatic bladder cancer and hear from the principal investigator of the confirmatory trial.

Coverage of stories discussed this week on ascopost.com:

Lenvatinib Plus Pembrolizumab for Advanced Gastric Cancer

USPSTF Issues Draft Recommendation Statement on Screening for Lung Cancer

FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma

This week, we'll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll review two influential breast cancer studies presented during the ASCO20 Virtual Scientific Program: MINDACT and HER2CLIMB.

This week, we'll be hearing from the presenters of three abstracts focused on multiple myeloma presented during the ASCO20 Virtual Scientific Program.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we'll be hearing from the presenters of three abstracts focused on multiple myeloma presented during the ASCO20 Virtual Scientific Program.